JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

JNJ

192.13

-0.43%↓

ABT

126.16

-2.02%↓

MDT

94.35

-2.11%↓

VEEV

290.48

+0.43%↑

A

147.3

+0.98%↑

Search

Sarepta Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

21.92 -2.75

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.28

Max

22.7

Pagrindiniai rodikliai

By Trading Economics

Pajamos

644M

197M

Pardavimai

-134M

611M

P/E

Sektoriaus vid.

27.205

37.461

Pelno marža

32.22

Darbuotojai

1,372

EBITDA

543M

174M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+4.28% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

732M

2.4B

Ankstesnė atidarymo kaina

24.67

Ankstesnė uždarymo kaina

21.92

Naujienos nuotaikos

By Acuity

17%

83%

24 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Sarepta Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-29 15:04; UTC

Pagrindinės rinkos jėgos

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

2025-07-21 11:31; UTC

Pagrindinės rinkos jėgos

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

2025-03-31 14:19; UTC

Pagrindinės rinkos jėgos

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

2025-08-11 11:48; UTC

Uždarbis

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025-08-11 11:11; UTC

Uždarbis

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025-07-29 21:11; UTC

Uždarbis

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

2025-07-29 12:14; UTC

Uždarbis

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

2025-07-29 11:46; UTC

Uždarbis

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

2025-07-21 12:53; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

2025-07-21 11:17; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

2025-07-21 10:25; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

2025-07-21 09:50; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025-07-21 09:12; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025-07-17 16:44; UTC

Uždarbis

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

2025-07-17 13:48; UTC

Uždarbis

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

2025-07-17 10:57; UTC

Uždarbis

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

2025-07-17 09:08; UTC

Karštos akcijos

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

2025-06-17 09:10; UTC

Karštos akcijos

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025-06-17 08:59; UTC

Karštos akcijos

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025-06-16 08:55; UTC

Karštos akcijos

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Akcijų palyginimas

Kainos pokytis

Sarepta Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

4.28% į viršų

12 mėnesių prognozė

Vidutinis 24.35 USD  4.28%

Aukščiausias 80 USD

Žemiausias 5 USD

Remiantis 24 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sarepta Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

24 ratings

6

Pirkti

13

Laikyti

5

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 62.47Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

24 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat